In the past few years, multispecific antibodies, such as trispecific, bispecific, and tetraspecific, have become popular in antibody therapeutics. Compared to conventional monospecific antibodies ...

Ichnos launched with a running start in 2019 when it was spun-out as an innovation unit by generics leader Glenmark, and subsequently focused on developing novel multispecific antibody ...

Biomissile Pharmaceuticals Co. Ltd. is developing multispecific antibodies that overcome resistance associated with antibody-drug conjugates via its next-generation natural killer (NK) cell engagers.

The funding is expected to support the development of a second novel multispecific antibody to SARS-CoV-2 from preclinical through Phase 1 trials, as well as preclinical work on gene-based ...

Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC and petosemtamab monotherapy in 2/3L r/m HNSCC enrolling; expected to be substantially ...

Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using ...